Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRXBiotechnology
+$0.07 today
- Market cap
- $417.57M
- Beta
- 1.48
- P/E (TTM)
- -8.5
- EPS (TTM)
- -$0.74
Volume 1.21M
Average 0.22M
EPRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $10.95M rose 184.4% year over year, ahead of the +72.6% change in trailing-twelve-month research & development. Sequentially, it rose 39.2% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +184.4% holds above the trailing-twelve-month pace of +72.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
Mixed currencies · from the income statement
- Latest · FY2025
- 29.51M USD
- Year-over-year change
- +83.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.51M | +83.6% |
| FY2024 | 2024-12-31 | 16.07M | +4.8% |
| FY2023 | 2023-12-31 | 15.33M | — |
| FY2022 | 2022-12-31 | 13.63M | +79.6% |
| FY2021 | 2021-12-31 | 7.59M | — |
Research & Development vs competitors
How EPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +72.6% is the 2nd highest of 9, against a peer median of +35.0%.
- Over three fiscal years its annual growth of +29.4% compares with a peer median of +11.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €83.61M EUR | -8.0% | +11.4% | 1865.0% | |
| LTM Mar 2026 | $62.82M USD | +25.5% | -7.1% | 3539.3% | |
| LTM Mar 2026 | $60.48M USD | +28.2% | +38.4% | 184.8% | |
| LTM Mar 2026 | $57.75M USD | +141.5% | +89.7% | — | |
| LTM Mar 2026 | $46.96M USD | +41.8% | +36.4% | — | |
| LTM Mar 2026 | $40.3M USD | -12.6% | +4.1% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $27.18M USD | +72.6% | +29.4% | — |
| LTM Sep 2026 | $23.16M USD | +47.2% | -19.1% | — | |
| LTM Mar 2026 | $16.62M USD | +61.4% | +12.0% | 114.8% | |
| LTM Mar 2026 | $3.93M USD | — | — | — | |
| Peer median (excluding EPRX) | — | +35.0% | +11.7% | 1024.9% | |
Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 112.38K | 0 | 0 | 163.47K | 331.89K |
| Gross Profit | (112.38K) | 0 | 0 | (163.47K) | (331.89K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.59M | 13.63M | 15.33M | 16.07M | 29.51M |
| Selling, General & Admin | 6.97M | 3.99M | 5.63M | 10.92M | 17.1M |
| Operating Expenses | 14.65M | 17.62M | 20.97M | 26.99M | 53.33M |
| Depreciation & Amortization | 87.47K | 147.89K | 117.1K | 171.6K | 331.89K |
| EBITDA | (17.22M) | (17.86M) | (20.78M) | (24.95M) | (53.33M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (14.65M) | (17.62M) | (20.97M) | (26.99M) | (53.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 51.55K | 431.8K | 649.75K | 1.16M | 1.41M |
| Interest Expense | 1.02M | 982.86K | 881.05K | 603.17K | 0 |
| Other Income / Expenses | (3.68M) | (1.37M) | (814.93K) | 1.26M | (212.94K) |
| Income Before Tax | (18.33M) | (18.99M) | (21.78M) | (25.73M) | (53.87M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 27.42K | 1.8K | 26.65K |
| Net Income | (18.03M) | (18.49M) | (21.25M) | (25.49M) | (53.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.63) | (0.96) | (0.88) | (0.76) | (1.05) |
| EPS (Diluted) | (1.63) | (0.96) | (0.88) | (0.76) | (1.05) |
| Weighted Avg Shares | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
| Weighted Avg Shares (Diluted) | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
Intrinsic Alpha fair value
Locked
Current Price
$6.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.